Literature DB >> 15036562

Effects of axonal injury on ganglion cell survival and glutamate homeostasis.

Christian K Vorwerk1, David Zurakowski, Luann M McDermott, Christian Mawrin, Evan B Dreyer.   

Abstract

Axonal trauma leads to a series of pathologic events that can culminate in neuronal death. Optic nerve crush can be used to explore histologic and molecular changes in traumatic central nervous system malfunction. Although the precise mechanisms of retinal ganglion cell death after optic nerve crush have not been elucidated, glutamate antagonists can protect retinal ganglion cells after axotomy. We, therefore, evaluated the effect of optic nerve crush on levels of extracellular glutamate. Ganglion cell survival and extracellular glutamate levels were assessed from 1 to 28 days after optic nerve crush in Long-Evans rats. Optic nerve crush led to a rise in extracellular glutamate; this rise was blocked by treatment with memantine, riluzole, and nimodipine. Partial optic nerve crush leads to an increase in vitreal glutamate, perhaps through release of intracellular contents. This released glutamate can contribute to additional ganglion cell loss. Future work will help to additionally unravel the steps by which axotomy induces excitotoxic damage to ganglion cells, and perhaps indicate protective interventions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036562     DOI: 10.1016/S0361-9230(03)00075-3

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  13 in total

1.  Plasminogen activators promote excitotoxicity-induced retinal damage.

Authors:  Raghuveer S Mali; Mei Cheng; Shravan K Chintala
Journal:  FASEB J       Date:  2005-08       Impact factor: 5.191

Review 2.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  AMPA receptor mediated D-serine release from retinal glial cells.

Authors:  Steve J Sullivan; Robert F Miller
Journal:  J Neurochem       Date:  2010-11-19       Impact factor: 5.372

4.  Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy.

Authors:  N R Miller; A C Arnold
Journal:  Eye (Lond)       Date:  2014-07-04       Impact factor: 3.775

5.  Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.

Authors:  Tetsuya Akaishi; Noriko Himori; Takayuki Takeshita; Kazuo Fujihara; Tatsuro Misu; Toshiyuki Takahashi; Juichi Fujimori; Tadashi Ishii; Masashi Aoki; Toru Nakazawa; Ichiro Nakashima
Journal:  Brain Behav       Date:  2021-02-16       Impact factor: 3.405

6.  Immunoproteasome deficiency protects in the retina after optic nerve crush.

Authors:  Nathan J Schuld; Stacy A Hussong; Rebecca J Kapphahn; Ute Lehmann; Heidi Roehrich; Abrar A Rageh; Neal D Heuss; Wendy Bratten; Dale S Gregerson; Deborah A Ferrington
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

7.  PhTx3-4, a Spider Toxin Calcium Channel Blocker, Reduces NMDA-Induced Injury of the Retina.

Authors:  Nancy Scardua Binda; Charles Porto Petruceli Carayon; Rafael Mourão Agostini; Ana Cristina do Nascimento Pinheiro; Marta Nascimento Cordeiro; Marco Aurélio Romano Silva; Juliana Figueira Silva; Elizete Maria Rita Pereira; Claudio Antonio da Silva Junior; Célio José de Castro Junior; Andre Luiz Sena Guimarães; Marcus Vinicius Gomez
Journal:  Toxins (Basel)       Date:  2016-03-11       Impact factor: 4.546

8.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

9.  Traumatic optic neuropathy - to treat or to observe?

Authors:  Kristian Samardzic; Josip Samardzic; Zeljka Janjetovic; Ivan Samardzic; Sandra Sekelj; Leila Latic-Hodzic
Journal:  Acta Inform Med       Date:  2012-06

10.  Hydrogen-rich saline promotes survival of retinal ganglion cells in a rat model of optic nerve crush.

Authors:  Jing-chuan Sun; Tao Xu; Qiao Zuo; Ruo-bing Wang; Ai-qing Qi; Wen-luo Cao; Ai-jun Sun; Xue-jun Sun; Jiajun Xu
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.